Skip to main content
. 2021 Feb 20;57:5–17. doi: 10.1016/j.breast.2021.02.009

Table 11.

Comparability of patient baseline characteristics amongst studies reporting RFS for node-positive patients (subgroup).

Parameter SOLE FACE Kwak (2015)
Study design RCT RCT RWE
Age (median) LC: 60c
LI: 60c
L: 62c
A:62c
48.5a
Post-menopausal (%) LC: 77c
LI: 76c
L: 100
A: 100
51.5
T1 (%) LC: 47c
LI: 58c
L: 47c,b
A: 45.5c,b
51.5
Stage 1 (%) NR 0 25.2
ER+ (%) LC: 98c
LI: 97.9c
L: 98.4c
A: 98.9c
93.2
PR+ (%) LC: 80c
LI: 78c
L: 79.8c
A: 79.4c
81.6

Abbreviations: A = anastrozole; ER = estrogen receptor; L = letrozole; LC = continuous letrozole; LI = intermittent letrozole; NR = not reported; PR = progesterone receptor; RCT = randomized controlled trial; RFS = recurrence-free survival; RWE = real-world evidence.

a

Mean age.

b

Includes T1 and T0 patients.

c

Full cohort (not exclusively HR+/HER2-).